Semaglutide offers new route to cardiovascular risk reduction
RESEARCH HIGHLIGHT
30 November 2023
In people with cardiovascular disease (without diabetes) and overweight or obesity, the GLP-1 receptor agonist semaglutide significantly reduced the risk of major cardiovascular events.
留言 (0)